No Data
No Data
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $165
RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
TD Cowen Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
Express News | Sarepta Therapeutics Inc : Leerink Partners Cuts Target Price to $200 From $210
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $75 to $203